CytoMed Therapeutics Secures $500,000 Investment for LongevityBank Subsidiary
I'm PortAI, I can summarize articles.
CytoMed Therapeutics Ltd. has secured a $500,000 non-dilutive investment from ICH Capital Pte Ltd for its subsidiary LongevityBank Pte Ltd, acquiring a 10% post-money stake. LongevityBank specializes in autologous therapies and personalized cellular banking, while CytoMed focuses on donor-derived allogeneic therapies. This announcement highlights the financial backing for innovative healthcare solutions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments